Andrew J. Piper-Valillo

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 91 citations · Full text

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett et al. · Clinical Cancer Research · 2023 · 35 citations · Full text

Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC)

Andrew J. Piper-Valillo, Jennifer L. Clark, Jose Mercado-Matos et al. · PLoS ONE · 2019 · 30 citations · Full text

Tumor Biology, Insulin Signaling, Irs-2 Expression Levels +14

Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells

Jose Mercado-Matos, Jennifer L. Clark, Andrew J. Piper-Valillo et al. · Journal of Biological Chemistry · 2017 · 24 citations · Full text

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC

Allison E.B. Chang, Andrew J. Piper-Valillo, Raymond H. Mak et al. · The Oncologist · 2024 · 15 citations · Full text